Published in Cancer Weekly, July 13th, 2004
For the year ended March 31, 2004, revenues were $2,416,000, as compared to $1,609,000 for the year ended March 31, 2003.
The increase was primarily attributable to revenues from research and testing agreements. Loss from operations for the year ended March 31, 2004, was $12,866,000, as compared to a loss from operations of $4,693,000 for the year ended March 31, 2003. The loss was largely due to noncash compensation expense recorded related to the vesting of common stock, options, and warrants issued during the year, which was approximately...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.